CHARLES RIVER LABORATORIES (CRL) Stock Fundamental Analysis
NYSE:CRL • US1598641074
172.84 USD
+5.28 (+3.15%)
Last: Feb 26, 2026, 01:59 PM
CRL gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. CRL has an average financial health and profitability rating. CRL is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year CRL was profitable.
- In the past year CRL had a positive cash flow from operations.
- Of the past 5 years CRL 4 years were profitable.
- Each year in the past 5 years CRL had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -2.02%, CRL is in the better half of the industry, outperforming 60.34% of the companies in the same industry.
- With a Return On Equity value of -4.56%, CRL perfoms like the industry average, outperforming 58.62% of the companies in the same industry.
- The Return On Invested Capital of CRL (6.60%) is better than 75.86% of its industry peers.
- CRL had an Average Return On Invested Capital over the past 3 years of 6.85%. This is significantly below the industry average of 11.97%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.02% | ||
| ROE | -4.56% | ||
| ROIC | 6.6% |
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
1.3 Margins
- With a decent Operating Margin value of 12.51%, CRL is doing good in the industry, outperforming 72.41% of the companies in the same industry.
- CRL's Operating Margin has declined in the last couple of years.
- The Gross Margin of CRL (34.98%) is worse than 62.07% of its industry peers.
- In the last couple of years the Gross Margin of CRL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.51% | ||
| PM (TTM) | N/A | ||
| GM | 34.98% |
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CRL is destroying value.
- The number of shares outstanding for CRL has been reduced compared to 1 year ago.
- The number of shares outstanding for CRL has been reduced compared to 5 years ago.
- The debt/assets ratio for CRL is higher compared to a year ago.
2.2 Solvency
- CRL has an Altman-Z score of 2.37. This is not the best score and indicates that CRL is in the grey zone with still only limited risk for bankruptcy at the moment.
- CRL's Altman-Z score of 2.37 is fine compared to the rest of the industry. CRL outperforms 65.52% of its industry peers.
- The Debt to FCF ratio of CRL is 4.13, which is a neutral value as it means it would take CRL, 4.13 years of fcf income to pay off all of its debts.
- With a decent Debt to FCF ratio value of 4.13, CRL is doing good in the industry, outperforming 72.41% of the companies in the same industry.
- A Debt/Equity ratio of 0.68 indicates that CRL is somewhat dependend on debt financing.
- With a Debt to Equity ratio value of 0.68, CRL is not doing good in the industry: 72.41% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.68 | ||
| Debt/FCF | 4.13 | ||
| Altman-Z | 2.37 |
ROIC/WACC0.63
WACC10.45%
2.3 Liquidity
- CRL has a Current Ratio of 1.29. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
- CRL's Current ratio of 1.29 is on the low side compared to the rest of the industry. CRL is outperformed by 77.59% of its industry peers.
- CRL has a Quick Ratio of 1.02. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
- CRL has a Quick ratio of 1.02. This is in the lower half of the industry: CRL underperforms 77.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
- CRL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.39%.
- Measured over the past 5 years, CRL shows a small growth in Earnings Per Share. The EPS has been growing by 4.78% on average per year.
- Looking at the last year, CRL shows a decrease in Revenue. The Revenue has decreased by -0.85% in the last year.
- Measured over the past years, CRL shows a small growth in Revenue. The Revenue has been growing by 6.55% on average per year.
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%
3.2 Future
- CRL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.70% yearly.
- Based on estimates for the next years, CRL will show a small growth in Revenue. The Revenue will grow by 3.26% on average per year.
EPS Next Y6.87%
EPS Next 2Y8.98%
EPS Next 3Y8%
EPS Next 5Y8.7%
Revenue Next Year1.7%
Revenue Next 2Y3.17%
Revenue Next 3Y3.18%
Revenue Next 5Y3.26%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 16.81, the valuation of CRL can be described as correct.
- 91.38% of the companies in the same industry are more expensive than CRL, based on the Price/Earnings ratio.
- Compared to an average S&P500 Price/Earnings ratio of 27.05, CRL is valued a bit cheaper.
- A Price/Forward Earnings ratio of 15.73 indicates a correct valuation of CRL.
- Based on the Price/Forward Earnings ratio, CRL is valued cheaper than 91.38% of the companies in the same industry.
- CRL's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.03.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.81 | ||
| Fwd PE | 15.73 |
4.2 Price Multiples
- 94.83% of the companies in the same industry are more expensive than CRL, based on the Enterprise Value to EBITDA ratio.
- CRL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CRL is cheaper than 89.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.41 | ||
| EV/EBITDA | 11.24 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)2.45
PEG (5Y)3.52
EPS Next 2Y8.98%
EPS Next 3Y8%
5. Dividend
5.1 Amount
- CRL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSE:CRL (2/26/2026, 1:59:49 PM)
172.84
+5.28 (+3.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-18 2026-02-18/bmo
Earnings (Next)05-05 2026-05-05/bmo
Inst Owners107.25%
Inst Owner Change3.98%
Ins Owners0.89%
Ins Owner Change4.42%
Market Cap8.51B
Revenue(TTM)4.02B
Net Income(TTM)-144.34M
Analysts78.26
Price Target206.28 (19.35%)
Short Float %5.53%
Short Ratio3.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.93%
Min EPS beat(2)0.98%
Max EPS beat(2)2.88%
EPS beat(4)4
Avg EPS beat(4)9.75%
Min EPS beat(4)0.98%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)9.14%
EPS beat(12)12
Avg EPS beat(12)7.96%
EPS beat(16)16
Avg EPS beat(16)6.74%
Revenue beat(2)1
Avg Revenue beat(2)0.06%
Min Revenue beat(2)-0.27%
Max Revenue beat(2)0.38%
Revenue beat(4)3
Avg Revenue beat(4)1.83%
Min Revenue beat(4)-0.27%
Max Revenue beat(4)3.74%
Revenue beat(8)6
Avg Revenue beat(8)1.34%
Revenue beat(12)9
Avg Revenue beat(12)1.37%
Revenue beat(16)11
Avg Revenue beat(16)1.18%
PT rev (1m)6.12%
PT rev (3m)14.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.08%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)0.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.81 | ||
| Fwd PE | 15.73 | ||
| P/S | 2.12 | ||
| P/FCF | 16.41 | ||
| P/OCF | 11.53 | ||
| P/B | 2.69 | ||
| P/tB | 140.89 | ||
| EV/EBITDA | 11.24 |
EPS(TTM)10.28
EY5.95%
EPS(NY)10.99
Fwd EY6.36%
FCF(TTM)10.53
FCFY6.09%
OCF(TTM)14.99
OCFY8.67%
SpS81.58
BVpS64.3
TBVpS1.23
PEG (NY)2.45
PEG (5Y)3.52
Graham Number121.95
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.02% | ||
| ROE | -4.56% | ||
| ROCE | 8.35% | ||
| ROIC | 6.6% | ||
| ROICexc | 6.84% | ||
| ROICexgc | 14.71% | ||
| OM | 12.51% | ||
| PM (TTM) | N/A | ||
| GM | 34.98% | ||
| FCFM | 12.91% |
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
ROICexc(3y)7.1%
ROICexc(5y)7.66%
ROICexgc(3y)16.12%
ROICexgc(5y)18.95%
ROCE(3y)8.67%
ROCE(5y)9.34%
ROICexgc growth 3Y-11.32%
ROICexgc growth 5Y-5.63%
ROICexc growth 3Y-6.27%
ROICexc growth 5Y-3.36%
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
F-Score5
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.68 | ||
| Debt/FCF | 4.13 | ||
| Debt/EBITDA | 2.36 | ||
| Cap/Depr | 54.34% | ||
| Cap/Sales | 5.46% | ||
| Interest Coverage | 4.94 | ||
| Cash Conversion | 81.47% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | 2.37 |
F-Score5
WACC10.45%
ROIC/WACC0.63
Cap/Depr(3y)73.38%
Cap/Depr(5y)82.63%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
EPS Next Y6.87%
EPS Next 2Y8.98%
EPS Next 3Y8%
EPS Next 5Y8.7%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%
Revenue Next Year1.7%
Revenue Next 2Y3.17%
Revenue Next 3Y3.18%
Revenue Next 5Y3.26%
EBIT growth 1Y-8.84%
EBIT growth 3Y-8.7%
EBIT growth 5Y2.04%
EBIT Next Year26.23%
EBIT Next 3Y12.9%
EBIT Next 5Y7.36%
FCF growth 1Y3.37%
FCF growth 3Y20.69%
FCF growth 5Y6.41%
OCF growth 1Y0.42%
OCF growth 3Y5.98%
OCF growth 5Y6.18%
CHARLES RIVER LABORATORIES / CRL FAQ
What is the fundamental rating for CRL stock?
ChartMill assigns a fundamental rating of 4 / 10 to CRL.
What is the valuation status of CHARLES RIVER LABORATORIES (CRL) stock?
ChartMill assigns a valuation rating of 6 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.
How profitable is CHARLES RIVER LABORATORIES (CRL) stock?
CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for CRL stock?
The Earnings per Share (EPS) of CHARLES RIVER LABORATORIES (CRL) is expected to grow by 6.87% in the next year.